Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage III non-small-cell lung cancer: A dosimetric study

Clinical Lung Cancer

Volumn 12, Issue 4, 2011, Pages 252-257

  Nichols Jr , R Charles ^a   Huh, Soon ^a   Henderson, Randal ^a   Mendenhall, Nancy ^a   Flampouri, Stella ^a   Li, Zuofeng ^a   D'Agostino, Harry ^a   Cury, J Davis ^a   Pham, Dat ^a   Hoppe, Bradford ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Bone marrow exposure; Chemotherapy; Normal lung exposure; Proton therapy; Radiotherapy

Indexed keywords

COBALT;

ARTICLE; BONE MARROW; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DOSIMETRY; ESOPHAGUS; HEART; HUMAN; INOPERABLE CANCER; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LUNG; LUNG NON SMALL CELL CANCER; PHOTON THERAPY; PROTON THERAPY; RADIATION DOSE DISTRIBUTION; RADIATION DOSE VOLUME; RADIATION EXPOSURE; RADIOLOGICAL PARAMETERS; SPINAL CORD; TREATMENT OUTCOME; TREATMENT PLANNING;

BONE MARROW; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG; LUNG NEOPLASMS; NEOPLASM STAGING; PROTONS; RADIOTHERAPY, INTENSITY-MODULATED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79960366553     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.027     Document Type: Article

References (29)

1. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692-9. (Pubitemid 29415225)
2. Curran W, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unre-sected stage III NSCLC: RTOG 9410 [Abstract]. J Clin Oncol 2003; 22:621.
3. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Tho-racique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005; 23:5910-7.
4. Bradley JD, Moughan J, Graham MV, et al. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys 2010; 77:367-72.
5. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008; 26:2457-63.
6. Schild SE, McGinnis WL, Graham D, et al. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65:1106-11.
7. Giraud P, Antoine M, Larrouy A, et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 2000; 48:1015-24.
8. Yeung AR, Li JG, Shi W, et al. Tumor localization using cone-beam CT reduces setup margins in conventionally fractionated radiotherapy for lung tumors. Int J Radiat Oncol Biol Phys 2009; 74:1100-7.
9. Miralbell R, Lomax A, Cella L, et al. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 2002; 54:824-9.
10. Kozak KR, Adams J, Krejcarek SJ, et al. A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyo-sarcomas. Int J Radiat Oncol Biol Phys 2009; 74:179-86.
11. Yock T, Schneider R, Friedmann A, et al. Proton radiotherapy for orbital rhabdo-myosarcoma: clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys 2005; 63:1161-8. (Pubitemid 41509195)
12. St Clair WH, Adams JA, Bues M, et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004; 58:727-34. (Pubitemid 38221128)
13. Lee CT, Bilton SD, Famiglietti RM, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys 2005; 63: 362-72. (Pubitemid 41317152)
14. Krengli M, Hug EB, Adams JA, et al. Proton radiation therapy for retinoblastoma: comparison of various intraocular tumor locations and beam arrangements. Int J Radiat Oncol Biol Phys 2005; 61:583-93. (Pubitemid 40164456)
15. Weber DC, Rutz HP, Pedroni ES, et al. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. Int J Radiat Oncol Biol Phys 2005; 63:401-9. (Pubitemid 41317156)
16. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahl-enther Onkol 1999; 175 Suppl 2:57-63. (Pubitemid 29533454)
17. Hug EB, Loredo LN, Slater JD, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999; 91:432-9. (Pubitemid 29404435)
18. Hoppe BS, Flampouri S, Li Z, et al. Cardiac sparing with proton therapy in con-solidative radiation therapy for Hodgkin lymphoma. Leuk Lymphoma 2010; 51: 1559-62.
19. Egger E, Zografos L, Schalenbourg A, et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys 2003; 55:867-80. (Pubitemid 36286989)
20. Gragoudas E, Li W, Goitein M, et al. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 2002; 120:1665-71. (Pubitemid 36401801)
21. Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65:1087-96.
22. Marcus RB Jr, Million RR. The incidence of myelitis after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys 1990; 19:3-8. (Pubitemid 20239777)
23. Shi W, Hsi W, Li Z, et al. Tumor shrinkage during proton based chemo-radiother-apy for non-small cell lung cancer necessitate adaptive replanning during treatment. Poster presented at the American Radium Society 91st Annual Meeting. April 21, 2009.
24. Schild SE. Elective Nodal Irradiation (ENI) doesn't appear to provide a clear benefit for patients with unresectable non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2008; 72:311-2.
25. Rosenzweig KE, Sura S, Jackson A, et al. Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol 2007; 25:5557-61.
26. Senan S, Burgers S, Samson MJ, et al. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys 2002; 54:999-1006. (Pubitemid 35299439)
27. Kim BT, Lee KS, Shim SS, et al. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT-a prospective study. Radiology 2006; 241:501-9. (Pubitemid 44632897)
28. Al Sarraf N, Aziz R, Gately K, et al. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative me-diastinal uptake on positron emission tomography. Eur J Cardiothorac Surg 2008; 33:104-9. (Pubitemid 350266343)
29. Videtic GM, Rice TW, Murthy S, et al. Utility of positron emission tomography compared with mediastinoscopy for delineating involved lymph nodes in stage III lung cancer: insights for radiotherapy planning from a surgical cohort. Int J Radiat Oncol Biol Phys 2008; 72:702-6.